Neoadjuvant Cabazitaxel Plus Abiraterone/Leuprolide Acetate in High-Risk Prostate Cancer Patients: ACDC-RP Phase II Trial

CONCLUSION: Neoadjuvant cabazitaxel addition to abiraterone acetate/leuprolide acetate prior to RP did not improve pCR/MRD in clinically localized, high-risk PCa.PMID:37439809 | DOI:10.1158/1078-0432.CCR-23-0731

Source: Clinical Prostate Cancer - July 13, 2023 Category: Cancer & Oncology Authors: Neil E Fleshner Rashid K Sayyid Aaron R Hansen Joseph L K Chin Ricardo Fernandes Eric Winquist Theodorus van der Kwast Joan Sweet Katherine Lajkosz Miran Kenk Karen Hersey Rosette Veloso Doron Berlin Jaime O Herrera-Caceres Srikala Sridhar Madeleine Mouss Source Type: research